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Abstract
Background: To investigate the in vitro and in vivo antitumor activity of dual PI3K/mTOR inhibitor BEZ235
(NVP-BEZ235) in HER2-positive gastric cancer.
Methods: HER2-positive breast cancer cell line (BT474), HER2-positive (NCI-N87 and SNU216), and HER2-negative
(MKN45) gastric cancer cell lines were used in this study. Cell viability, cell cycle, and HER2 downstream signaling
pathways were analyzed using the MTS assay, flow cytometry, and western blotting, respectively. For the in vivo
experiments, HER2-positive gastric cancer patient-derived xenografts were treated with BEZ235 to assess its
antitumor activity.
Results: The sensitivity of trastuzumab in BT474 cells was higher than that for NCI-N87 and SNU216 cells, which
may be partially attributed to continuously active HER2 downstream signaling pathway. BEZ235 inhibited the
proliferation of NCI-N87 and SNU216 cells in vitro in a dose-dependent manner by inducing the cell cycle arrest at
the G1 phase. BEZ235 demonstrated greater inhibitory effects than trastuzumab, a unique targeted drug, in both
the in vitro and in vivo set of experiments. Additionally, our results indicate that BEZ235 displayed some synergism
with trastuzumab. BEZ235 exhibited its antitumor activity in gastric cancer by inhibiting important HER2
downstream signaling pathways, as indicated by the inhibition of phosphorylated AKT and S6.
Conclusion: The present study has demonstrated, for the first time, the antitumor activity of BEZ235 against
HER2-positive gastric cancer in patient-derived xenografts, as well its synergistic interaction with trastuzumab.
These important findings can be utilized to facilitate the design of future clinical trials.
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Background
In approximately 15–20 % of gastric cancer cases, gastric
cells overexpress human epidermal growth factor recep-
tor 2 (HER2) and/ undergo gene amplification [1]. Tras-
tuzumab, a humanized monoclonal antibody that targets
the HER-2/neu gene, has been widely used to treat
HER2-positive breast cancer and gastric cancer. Treat-
ment with trastuzumab showed significantly improved
clinical outcomes in patients; however, HER2-positive
gastric cancer patients exhibited reduced sensitivity to
trastuzumab than the breast cancer patients [2, 3]. Clin-
ical reports indicate that the objective response rate
(ORR) of trastuzumab in HER2-positive gastric cancer
was lower than that of HER2-positive breast cancer
(about 16 % vs. 26 %) [2, 4]. This suggests that HER2-
positive gastric cancer has its own molecular characteris-
tics, and therefore, exploring the mechanism that
induces differences in the treatment response may even-
tually provide new therapeutic strategies.
Numerous potential mechanisms for trastuzumab re-
sistance have been reported, such as alterations in the
HER2 structure or surroundings, dysregulation of HER2
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downstream signaling effectors, and HER2 interac-
tions with other membrane receptors. Of these, the
activation of HER2 downstream signaling pathways
PI3K/AKT/mTOR and RAS/RAF/MEK/MAPK signifi-
cantly contributed to trastuzumab resistance [5, 6]. It
has been previously reported that trastuzumab re-
duced the phosphorylation levels of AKT (p-AKT)
and S6 (p-S6) in BT474, a trastuzumab-breast cancer
cell line. In contrast, trastuzumab treatment in
trastuzumab-resistant cell line BT474-TR had no ef-
fects on p-AKT and p-S6, indicating that resistance is
associated with a failure to inhibit PI3K/mTOR sig-
naling [7, 8].
The association between trastuzumab treatment and
PI3K-AKT-mTOR pathway alterations in gastric cancer
has not been widely studied. Hence, the objective of this
study was to identify alternations in the HER2 down-
stream signaling pathways post trastuzumab treatment
using both in vitro and in vivo techniques. Our results
will help explore more strategies for improving trastuzu-
mab sensitivity in HER2-positive gastric cancer.
Methods
Cell lines, trastuzumab, and inhibitors
MKN45 and NCI-N87 cell lines were provided by Professor
You-yong Lv (Peking University Cancer Hospital and
Institute), the BT474 cell line was purchased from Peking
Union Medical College, and the SNU216 cell line was ob-
tained from Fudan University Shanghai Cancer Center.
All the cell lines were cultured in RPMI 1640 medium
(Gibco BRL, MD, USA) supplemented with 10 % fetal bo-
vine serum (Gibco BRL), and incubated in a humidi-
fied incubator (37 °C) supplemented with 5 % CO2.
Trastuzumab was purchased from Shanghai Roche
Pharmaceutical Ltd., whereas BEZ235, Everolimus, and
AZD6244 were purchased from Selleck China. For the
in vitro studies, BEZ235, Everolimus, and AZD6244 were
dissolved in dimethyl sulfoxide (DMSO) at a stock con-
centration of 10 mmol/L and stored at −20 °C until fur-
ther use. Trastuzumab was dissolved in 0.9 % NaCl at a
stock concentration of 20 μg/μL and stored at −80 °C,
and BEZ235 was formulated in 0.9 % NaCl as a homoge-
neous suspension (9 mg/mL) and stored at 4 °C until
further use in the in vivo experiments.
Cell viability assay
Cells were seeded at a density of 2000 cells per well
in a 96-well plate and incubated overnight in
complete medium. Cells were treated with either tras-
tuzumab, BEZ235, Everolimus, AZD6244 alone, or
trastuzumab combined with BEZ235 or Everolimus or
AZD6244. After 72 h of incubation, cell viability was
determined using the MTS tetrazolium substrate
(CellTiter 96 Aqueous One Solution Cell Proliferation
Assay, Promega, Madison, WI, USA) following the
manufacturer’s instructions. The absorbance was mea-
sured at 490 nm using a spectrophotometer. All ex-
periments were repeated three times with at least
triplicate readings for each concentration.
Western blotting analysis
Total protein was extracted from cell pellets using
CytoBuster Protein Extraction Reagent (Merck Millipore,
Darmstadt, Germany). Protein concentration was mea-
sured by using a BCA Protein Assay Kit (Beyotime
Biotechnology, Jiangsu, China), and 30 μg of protein
from each sample was separated by 12 % SDS-PAGE.
After transfer, the nitrocellulose membrane (GE Healthcare,
Piscataway, NJ) was incubated with the corresponding pri-
mary antibodies at 4 °C overnight and secondary antibodies
at room temperature for 1 h (the antibody list is shown in
Additional file 1: Table S1). Proteins were visualized
using ECL plus Western Blotting Detection Reagents
(GE Healthcare).
Cell cycle assay
After 48 h treatment, the cells were harvested and fixed
in cold 70 % ethanol overnight at 4 °C. Cells were
stained in the dark with 50 μg/mL propidium iodide (BD
Biosciences), and incubated at room temperature for
30 min. Cell cycle analysis was performed by FACS Cali-
bur system (BD Biosciences) and analyzed using the
ModFit 3.0 software (BD Biosciences).
Annexin V apoptosis assay
Cell apoptosis was conducted by staining with Annexin
V-Allophycocyanin (APC) and 7-amino-actinomycin
(7-AAD) (BD Biosciences, Erembodegem, Belgium) for
15 min at room temperature in the dark, followed by
flow cytometric analysis within 1 h (BD Biosciences).
Cell apoptosis was analyzed using the WinMDI 2.9
software (BD Biosciences).
Xenograft models in non-obese diabetic/severe combined
immunodeficiency (NOD/SCID) mice
Two different xenograft models were used in the
present study. NCI-N87 cells (cell density: 1 × 106)
were suspended in 0.1 mL of phosphate-buffered sa-
line (PBS), and injected subcutaneously into the dor-
sal right flank of 6-week-old NOD/SCID mice (Beijing
HFK Bio-Technology Co., LTD, Beijing, China). Two
HER2-positive patient-derived xenografts (PDX) were
obtained using our previously published report. HER2
expression and the characteristics of these two pa-
tients are shown in Additional file 1: Figure S1 and
Table S2, respectively.
When the tumor volume reached approximately
150 mm3, the mice were randomly assigned to four groups
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(5 mice/group): (1) control group (physiological saline,
100 μL daily), (2) trastuzumab group (20 mg/kg body
weight, thrice weekly by intraperitoneal injection), (3)
BEZ235 group (45 mg/kg body weight, daily by gavage),
and (4) combination (BEZ235, 45 mg/kg body weight,
daily by gavage, and trastuzumab, 20 mg/kg body weight,
thrice weekly by intraperitoneal injection). The animals
were treated for 3 weeks. Tumor size and body weight
were measured twice weekly, and the tumor volume (V)
was calculated using the following formula: V = L ×W2/2
(L, long diameter of the tumor; W, short diameter of the
tumor). All patients signed written informed consent for
their samples to be used in the future study. The experi-
mental procedures involving animals were approved by in-
dependent ethics committee of Peking University Cancer
Hospital and carried out in accordance with the approved
guidelines. The study was undertaken in accordance with
the ethical standards of the World Medical Association
Declaration of Helsinki. Also, the animal work was ap-
proved by Peking University Cancer Hospital’s Institutional
Animal Care and Use Committee. All animal experimenta-
tion followed internationally recognized ARRIVE (Animal
Research: Reporting of In Vivo Experiments) guidelines.
Immunohistochemical staining
After the mice were sacrificed, the xenografts were iso-
lated, and formalin-fixed paraffin embedded (FFPE) tis-
sue blocks were prepared. Immunohistochemical (IHC)
staining was performed as described in our previous
study [9]. Briefly, after deparaffinization, hydration,
retrieval, and endogenous peroxidase treatment, 4-μm-
thick FFPE sections were incubated with the corre-
sponding primary antibodies (the dilutions of p-AKT,
p-ERK, and p-S6 were 1:100, 1:400, and 1:200, respect-
ively) overnight at 4 °C. The signal was detected follow-
ing incubation with IgG-HRP polymer (Cat. PV-6000,
ZSGB-BIO, Beijing, China) and diaminobenzidine sub-
strate. Each experiment included a negative control.
Sections were interpreted by 2 blinded, independent
professional pathologists from the Department of Pathology
of Peking University Cancer Hospital. As described previ-
ously, staining was scored based on the intensity of staining
(1, weak; 2, moderate; and 3, strong) and relative number of
cells stained (1: 0–10 %; 2: 11–50 %; and 3: 51–100 %). The
expression levels were defined as −, +, ++, and +++ based
on the median staining score (intensity score plus percent-
age score).
Statistical analysis
Statistical analysis was performed using the SPSS 18.0
software. For the in vitro studies, the differences be-
tween the groups were analyzed using the unpaired two-
tailed t-test, one-way ANOVA or factorial analysis. In
the in vivo studies, the tumor growth amongst different
groups was compared using repeated measures ANOVA.
P <0.05 was considered statistically significant.
Results
Trastuzumab sensitivity in HER2-positive cancer cells and
its effects on the HER2 signaling pathway
The antiproliferative effects of trastuzumab were assessed
in HER2-positive breast cancer cell BT474, and gastric
cancer cell lines NCI-N87 and SNU216 using a 10-
dimensional drug response assay. Consistent with the clin-
ical studies, the sensitivity of trastuzumab in BT474 was
higher than that in NCI-N87 and SNU216 (Fig. 1a).
We further evaluated the phosphorylation status of
the key proteins in the HER2 signaling cascade.
Treatment of BT474 with 1 μmol/L trastuzumab
caused almost complete dephosphorylation of both
AKT and S6. In contrast, trastuzumab treatment
inhibited the phosphorylation of AKT, with no effects
Fig. 1 The sensitivity of trastuzumab in HER2-positive cancer cells and its effects on the HER2 signaling pathway. a The sensitivity of trastuzumab in
HER2-positive breast cancer cells (BT474) was higher than that observed in HER2-positive gastric cancer cells (NCI-N87 and SNU216). b Phosphorylated
AKT and S6 were both inhibited by trastuzumab in BT474 cells, however, only phosphorylated AKT was inhibited by trastuzumab in NCI-N87 and
SNU216 cells. Proliferation assays are expressed as the Mean ± S.D of three replicate assays. Western blots were repeated at least twice. * P <0.01
according to factorial analysis. Cropped blots were used because the same experimental conditions were used for running all the gels
Zhu et al. BMC Cancer  (2015) 15:894 Page 3 of 10
on the levels of p-S6 in NCI-N87 and SNU216 cells,
indicating that the activity of HER2 downstream sig-
naling pathway influenced the sensitivity of trastuzu-
mab (Fig. 1b).
BEZ235 strongly inhibits the proliferation of HER2-postive
gastric cancer cells in a dose-dependent manner
To further elucidate the effects of trastuzumab on the
HER2 downstream signaling pathways, 3 signaling
Fig. 2 Antiproliferative activity of inhibitors in HER2-postive gastric cancer cell lines. BEZ235 showed superior inhibitory activity against NCI-N87
and SNU216 cells compared to trastuzumab, Everolimus, or AZD6244 (a–b). Moreover, the synergism was only observed in the combination of
trastuzumab with BEZ235 (P = 0.000 for all) (c and d), and not in the combination of trastuzumab with Everolimus or AZD6244 (e–h). Proliferation
assays are expressed as the Mean ± S.D of three replicate assays. P values calculated by factorial analysis
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inhibitors — the dual PI3K/mTOR inhibitor BEZ235,
mTOR inhibitor Everolimus, and ERK inhibitor
AZD6244 — alone or in combination with trastuzumab,
were examined in vitro. When used alone, trastuzumab,
BEZ235, Everolimus, and AZD6244 inhibited the prolif-
eration of NCI-N87 and SNU216 in a dose-dependent
manner. However, compared to trastuzumab, Everolimus,
and AZD6244, PI3K/mTOR dual inhibitor BEZ235 exhib-
ited maximum inhibition in the proliferation of NCI-N87
and SNU216 cells (Fig. 2a and b).
Currently, trastuzumab is the only first-line target drug
for the treatment of advanced gastric cancer. We, there-
fore, analyzed the in vitro synergistic effects of trastuzu-
mab with BEZ235, Everolimus, or AZD6244. The results
indicated that trastuzumab showed maybe some syner-
gism with BEZ235 (all P = 0.000) (Fig. 2c and d), but no
synergism with AZD6244 or Everolimus (Fig. 2e–h).
BEZ235 specifically targets HER2-postive gastric cancer
cell lines
To confirm the specific activity of BEZ235 treatment on
HER2-positive gastric cancer, the antitumor activity of
BEZ235 was compared in HER2-positive (NCI-N87 and
SNU216) and HER2-negative (MKN45) gastric cancer
cell lines. The results indicated that the sensitivity of
BEZ235 in NCI-N87 and SNU216 was significantly
higher than that observed in MKN45 (P = 0.000) (Fig. 3a).
Also, the expression levels of p-AKT, p-ERK, and p-S6
in MKN45 cells were significantly lower than that of
NCI-N87 cells (Fig. 3b).
BEZ235 significantly inhibited the HER2 downstream
signaling pathways
Immunodetection assay for several HER2 downstream
signaling pathway molecules were conducted based on
the pervious observation that BEZ235 exerts antiprolif-
erative activity on gastric cancer cells. BEZ235 inhibited
the levels of both p-AKT and p-S6, whereas, trastuzu-
mab inhibited only p-AKT in NCI-N87 and SNU216
cells. Interestingly, treatment of NCI-N87 and SNU216
cells with a combination of BEZ235 and trastuzumab
completely suppressed the levels of p-AKT and p-S6,
with partial inhibition of p-ERK (Fig. 4a). Additionally,
treatment with either BEZ235 or trastuzumab did not
change the levels of p-ERK, but AZD6244 treatment
did reduce p-ERK levels with no changes in p-AKT
and p-S6. Everolimus resulted in complete dephos-
phorylation of S6, with a concomitant increase in
the phosphorylation of AKT. Also, p-ERK, p-AKT,
and p-S6 were not further inhibited by trastuzumab
combined with AZD6244 or Everolimus compared to
trastuzumab, AZD6244, or Everolimus alone (Fig. 4b).
Since BEZ235 alone significantly inhibited the cell
proliferation, PI3K/AKT/mTOR signaling pathway
may be more crucial for HER2-positive gastric can-
cer survival.
BEZ235 induced cell cycle arrest at the G1 phase
Cell cycle and cell apoptosis analyses were conducted
to explore the potential mechanisms responsible for
the inhibition of cell proliferation in gastric cancer
cells. The percentage of NCI-N87 and SNU216 cells
that accumulated in the G1 phase significantly in-
creased after treatment with trastuzumab alone (54.3
and 49.1 %, respectively), BEZ235 alone (61.3 and
56.5 %, respectively), or BEZ235 combined with tras-
tuzumab (68.5 and 72.2 %, respectively) compared to
the control (47.5 and 43.3 %, respectively) (Fig. 5a
and b). Concomitant with the cell cycle arrest at the
Fig. 3 BEZ235 specifically targets HER2-postive gastric cancer cell lines. a The sensitivity of BEZ235 in NCI-N87 and SNU216 cells was significantly
higher than that observed in MKN45 cells. b Western blotting analysis showed that the expression of p-AKT, p-ERK, and p-S6 in MKN45 cells was
significantly lower than that observed in NCI-N87 cells. Proliferation assays are expressed as the Mean ± S.D of three replicate assays. Western blots
were repeated twice. *P <0.01 according to factorial analysis. Cropped blots were used because the same experimental conditions were used for
running all the gels
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Fig. 4 Downregulation of the HER2 signaling pathway in vitro. a Treatment with BEZ235 in combination with trastuzumab led to complete
inhibition of p-AKT and p-S6, with partial inhibition of p-ERK. b p-ERK, p-AKT, and p-S6 were not further inhibited by trastuzumab combined with
AZD6244 or Everolimus compared to trastuzumab, AZD6244, and Everolimus monotherapy. The levels of p-AKT, p-ERK, and p-S6 were analyzed
by western blotting using specific monoclonal antibodies. β-Actin was used as a loading control. The phosphorylation levels of AKT, ERK, and S6
were quantified by using the software Image J. The data are expressed as the Mean ± S.D of three independent experiments. *P <0.01 by one-way
ANOVA or unpaired two-tailed t-test. Cropped blots were used because the same experimental conditions were used for running all the gels
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G1 phase, the expression of cyclin-dependent kinase
(CDK4) and cyclin D1 were downregulated (Fig. 5c).
However, cell apoptosis was not induced by treatment
with either BEZ235 or trastuzumab (Additional file 1:
Figure S2).
BEZ235 suppressed the growth of xenografts in vivo
NCI-N87 cells and biopsies from gastric cancer pa-
tients were subcutaneously inoculated into NOD/
SCID mice to establish NCI-N87 xenografts and PDX
in vivo. The growth of tumors treated with BEZ235
alone was significantly suppressed both in NCI-N87
xenografts and patient-derived xenografts (P = 0.000
for all) compared to the control or the trastuzumab
group. Treatment with BEZ235 combined with trastu-
zumab showed some synergistic inhibitory effects on
the in vivo xenografts,but the contribution due to the
synergism was relatively modest (P value was 0.014
for NCI-N87 xenograft; for two different PDXs, P
value were 0.036 and 0.03) compared to BEZ235
treatment alone (Fig. 6).
The in vitro results that p-AKT and p-S6 could be sig-
nificantly suppressed by BEZ235 in gastric cancer cell
lines were also validated in vivo. Tumor tissues from
treated mice xenografts were immunostained with p-
AKT, p-S6, and p-ERK antibodies. The results indicated
that BEZ235 effectively suppressed p-AKT and p-S6
(Fig. 6f ), which is consistent with the results presented
in Fig. 4. This suggests that the in vivo efficacy of
BEZ235 correlates with PI3K/mTOR target regulation.
Discussion
Trastuzumab has been widely used for the treatment
of HER2-positive breast cancer and gastric cancer,
and is currently the only first-line target drug for ad-
vanced gastric cancer [2]. However, the lower ORR of
trastuzumab in HER2-positive gastric cancer than that
of HER2-positive breast cancer prompted us to inves-
tigate the potential mechanisms that could provide
novel strategies for trastuzumab therapy in HER2-
positive gastric cancer.
Our results suggest that the continuously active HER2
downstream signaling pathways might be one of the
Fig. 5 BEZ235 alone or combined with trastuzumab induced cell cycle arrest at G1 phase. a–b Flow cytometric analysis showed that the
percentage of cells accumulated in G1 phase significantly increased after treatment with trastuzumab alone (54.3 and 49.1 %, respectively),
BEZ235 alone (61.3 and 56.5 %, respectively), or BEZ235 combined with trastuzumab (68.5 and 72.2 %, respectively), compared to the control (47.5
and 43.3 %, respectively). c The expression of CDK4 and cyclin D1 was further downregulated by BEZ235 combined with trastuzumab compared
to either one inhibitor used individually. The data are expressed as the Mean ± S.D of three independent experiments. *P <0.05 by one-way
ANOVA or unpaired two-tailed t-test. Cropped blots were used because the same experimental conditions were used for running all the gels
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mechanisms resulting in relatively lower sensitivity of
trastuzumab in HER2-positive gastric cancer than
breast cancer (Fig. 1). Based on these findings, three sig-
naling inhibitors — the dual PI3K/mTOR inhibitor
BEZ235, mTOR inhibitor Everolimus, and ERK inhibi-
tor AZD6244 — targeting the HER2 downstream path-
ways were screened. Compared to the other inhibitors,
BEZ235 showed therapeutic potential in clinical prac-
tice (Fig. 2). BEZ235 specifically inhibited the PI3K/
mTOR axis and exerted notable antiproliferative activ-
ity, indicating that PI3K/mTOR signaling pathway may
be more crucial for HER2-positive gastric cancer sur-
vival, and that intervention of this pathway may offer
better therapeutic options.
Preclinical studies have shown that the dual PI3K/
mTOR inhibitor BEZ235 demonstrated antitumor activ-
ity in pancreatic cancer and glioblastoma, amongst
others [10–12]. Fuereder et al. reported that BEZ235
inhibited the growth of NCI-N87, but not MKN45 and
MKN28 xenografts [13], suggesting that BEZ235 might
play a specific role in HER2-positive gastric cancer. To
validate this finding, a comparative analysis of BEZ235
sensitivity was conducted. The results from this analysis
demonstrated that the sensitivity of HER2-positive cells
(NCI-N87 and SNU216) was significantly higher than
that of the HER2-negative cells (MKN45) (P = 0.000)
(Fig. 3a). Also, the expression levels of p-AKT, p-ERK
and p-S6 in MKN45 cells were significantly lower
than the NCI-N87 cells (Fig. 3b), which further vali-
dated the fundamental finding of BEZ235 differential
sensitivity.
Several preclinical studies have examined the antitumor
activity of BEZ235 [8, 12, 14], and the promising results
from these have prompted clinicians to assess its efficacy
and safety in Phase I/II clinical trials (www.clinicaltrials.
gov). O’Brien et al. reported that BEZ235 could overcome
the resistance to HER2-targeted therapy in HER2-positive
breast cancer in both in vitro and in vivo studies [7].
BEZ235 can reverse PI3K/mTOR pathway hyperactivation
caused by the oncogenic mutations, and also inhibit
HER2-amplified BT474-TR cell proliferation. In the
present study, we explored the efficacy of BEZ235 in NCI-
N87 and SNU216 trastuzumab-sensitive cells. Therefore,
whether BEZ235 could overcome trastuzumab resistance
in trastuzumab-resistant HER2-positive gastric cancer
cells still remains uncertain. Further studies will be con-
ducted to investigate this using in vitro and in vivo
trastuzumab-resistant PDX models.
Fig. 6 Antitumor effects of trastuzumab and BEZ235 on HER2-positive gastric cancer patient-derived xenografts (PDX). The growth of tumors
treated with BEZ235 alone or combined with trastuzumab was significantly suppressed both in the NCI-N87 xenografts (a) and in 2 patient-
derived xenografts (b and c). BEZ235 combined with trastuzumab imparted synergistically inhibitory effects on the in vivo xenografts (a–e). Tumor
volumes are expressed as Mean ± S.D. Immunohistochemistry analysis showed that p-AKT, p-S6, and p-ERK were effectively inhibited by BEZ235
combined with trastuzumab compared to BEZ235 alone or trastuzumab alone (f). The scale bar represents 100 μm. P <0.05 by according to
repeated measures ANOVA
Zhu et al. BMC Cancer  (2015) 15:894 Page 8 of 10
Cell cycle arrest and cell apoptosis are common mecha-
nisms responsible for the inhibition of cell growth. Fuereder
et al. [13] reported that the in vitro antiproliferative activity
of BEZ235 correlated with a dose-dependent increase of
gastric cancer cells in the G1 phase of the cell cycle and
cyclin D1 downregulation. We confirmed these findings by
demonstrating that treatment with BEZ235 alone or in
combination with trastuzumab, effectively arrested the cell
cycle at the G1 phase, concurrent with the downregulation
of CDK4 and cyclin D1 (Fig. 5). Several investigators have
reported a controversial role of apoptosis on the antiprolif-
erative activity of BEZ235. Brachmann et al. reported that
BEZ235 could induce cell apoptosis in HER2-positive
breast cancer cells [15], but in our present study, BEZ235
treatment failed to induce apoptosis in NCI-N87 and
SNU216 cells (Additional file 1: Figure S2). Based on our
results, we concluded that BEZ235 could not induce a sig-
nificant apoptotic response, and that the cell cycle arrest at
the G1 phase predominantly affects gastric cancer cell pro-
liferation. However, we aim to further explore this mechan-
ism in our future studies.
The GRANITE-1 study indicated that patients with
advanced gastric cancer do not benefit from Everolimus
[16], although the mechanism behind this observation is
unclear. In this study, the results demonstrated that
Everolimus treatment inhibited p-S6, but led to in-
creased activation of p-AKT (Fig. 4b). These results
might be helpful in understanding the failure of Everoli-
mus in preventing cell proliferation in gastric cancer.
As shown in Fig. 4a, trastuzumab or BEZ235 treat-
ment alone failed to inhibit p-ERK, however, in combin-
ation, these two drugs could partially inhibit p-ERK.
One of the reasons that we observed this effect could be
due to a crosstalk between PI3K/AKT/mTOR and RAS/
RAF/MEK/MAPK pathways [17–20]. PI3K can activate
RAS through the recruitment of Gab/Shp2 by PIP3 [17],
followed by ERK activation. When the PI3K/AKT/
mTOR pathway was suppressed by BEZ235 combined
with trastuzumab, we observed a decrease in the levels
of p-ERK following RAS inhibition. This might explain
why BEZ235 had some synergistically inhibitory effects
with trastuzumab; however, the synergistic effect was
not obvious. Also, BEZ235 and trastuzumab are known
to target the PI3K/mTOR pathway. The results also indi-
cate that the ERK signaling pathway might not be im-
portant in HER2-positive gastric cancer survival.
Several new drugs such as cetuximab [21], bevacizu-
mab [22], and Everolimus [16] that initially demon-
strated antitumor activity in preclinical studies have
failed the clinical trials for the treatment of gastric can-
cer. The most important reason for this negative out-
come could be a lack of optimal preclinical animal
models. In the present study, patient-derived xenografts
models in addition to traditional animal models were
used, to confirm the reliability of the results. The results
from this study provide useful data to conduct clinical
studies for BEZ235 in the future.
Conclusions
To our knowledge, this is the first report that describes
a strong inhibitory activity of dual PI3K/mTOR inhibitor
BEZ235 in HER2-positive in vitro and in vivo gastric
cancer patient-derived xenografts, and this finding can
be utilized to design future clinical trials.
Additional file
Additional file 1: Figure S1. The expression of HER2 in two HER2-
positive patient-derived xenografts (PDXs). Cases 1 and 2 with HER2
positive expression of primary tumors maintained positive expression of
xenografts based on IHC and DISH results. Scale bars, 100 μm. Figure S2.
BEZ235 or trastuzumab did not induce cell apoptosis. Flow cytometry
analysis showed that the percentage of apoptotic cells did not increased
after treatment with trastuzumab alone (4.2 and 4.3 %, respectively),
BEZ235 alone (3.0 and 3.2 %, respectively), compared to the control
(4.0 and 5.2 %, respectively). The data are expressed as the mean ± s.d
of three independent experiments. *P >0.05 by one-way ANOVA or
unpaired two-tailed t-test. Table S1. Antibodies used in this study.
Table S2. The characteristics of two patients. (DOC 2229 kb)
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